March 2022 Edition


Authors stated that guidelines for adults aged >65 years have changed to the following:
• Adults aged >65 years who have not previously received PCV or whose previous vaccination history is unknown should receive 1 dose of PCV (either PCV20 or PCV15). When PCV15 is used, it should be followed by a dose of PPSV23.

To align as closely as possible to the new CDC guidelines, we will be modifying the Rise to Immunize™ (RIZE) campaign’s pneumococcal measure. Effective July 1, 2022 (Q3 2022, report due Oct. 14, 2022), the measure will be updated to the following:
• Measure 2 (Pneumococcal): Proportion of eligible patients who were administered any conjugate pneumococcal vaccine during the Measurement Year or are documented as up-to-date on their pneumococcal vaccination.

A few notes regarding these changes:
• As a reminder, our measures are designed for benchmarking purposes and should not be used in place of clinical guidelines.
• The RIZE team will provide updated Measurement Specifications, a Data Reporting Excel Template, and value set prior to the change.
• This change will not affect any of the data submissions for Reporting Quarters Q3 2019-Q2 2022, submitted on Feb. 15, 2022, April 15, 2022, or July 15, 2022. These submissions will continue to follow the current Measurement Specifications and be reported using the current value set.

Join us for the March webinar, “Pneumococcal 101,” where we will share more information about the new clinical guidelines and updates to our measures.

As always, please don’t hesitate to contact RiseToImmunize@amga.org with questions or for support.

Best,
- The RIZE Team

Webinar Preview
"Pneumococcal 101"

The March campaign webinar will feature Frank Colangelo, MD, MS-HQS, FACP. Dr. Colangelo is a founding physician and Chief Quality Officer with Premier Medical Associates, P.C. in Pittsburgh, PA, and serves as Director of the Outcomes Office for the Allegheny Health Network. Dr. Colangelo is dedicated to population health and a key leader in transforming patient-centered medical care, receiving recognition from NCQA. He serves on the AMGA Foundation Board of Directors and as a National Advisor for the RIZE campaign. Additionally, Dr. Colangelo is currently leading clinical guideline implementation changes for the pneumococcal vaccine at his organization. Join us on March 17 to learn about pneumococcal vaccination updates and best practices.
Upcoming Dates

March 9-12 — AMGA's 2022 Annual Conference in Las Vegas, NV (Learn more)

March 17 — Monthly campaign webinar: "Pneumococcal 101" at 2 p.m. ET (Register)

April 15 — Deadline to submit quarterly data (Learn more)

April 21 - Monthly campaign webinar: "Zoster 101" at 2 p.m. ET (Register)

Campaign Spotlight

A special thank you to all the members of our National Advisory Committee who provided feedback on how and when to update the campaign’s pneumococcal measure. We appreciate their contributions to designing this national initiative, as well as their ongoing guidance on campaign implementation and overall direction. View a list of our 12 National Advisors on our website.

Resource of the Month

The CDC’s PneumoRecs VaxAdvisor mobile app can help healthcare professionals stay informed as clinical guidance around pneumococcal vaccination changes. The app is designed for providers to quickly and easily determine which pneumococcal vaccine(s) a patient needs and when. This comprehensive tool incorporates recommendations for all ages, so all vaccination providers can benefit from using the app. Learn more about the mobile app on the CDC’s website.